Shots:

• EU approval is based on results of APOLLO P-III study involving 19 countries in ratio (2:1) assessing Onpattro vs PBO once q3w for 18mos showing safety and efficacy
• Onpattro RNA interference (RNAi) will be launch in Germany for the treatment of Hereditary Transthyretin-Mediated (hATTR) with improved QoL
• Onpattro is an IV RNAi therapeutic developed to treat Amyloidosis (hATTR Amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy. It is based on RNAi- a Nobel Prize-winning Mechanism and received EU and FDA approval in Aug 2018

Ref: Alnylam | Image: BusinessWire